Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the ...

Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes.

In an important regulatory win for Denmark’s Novo Nordisk, the US Food and Drug Administration (FDA) yesterday approved ...

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...

Find insight on Sanofi, ResMed, Lonza and more in the latest Market Talks covering the health care sector.

Jakob Grauslund, D.M.Sci., PhD, MD, from Odense University Hospital in Denmark, and colleagues prospectively evaluated the use of semaglutide and risk for NAION in people with type 2 diabetes.

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Eli Lilly (LLY 1.45%) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

Semaglutide, the active ingredient in Ozempic and Wegovy, is primarily manufactured in Denmark, although Novo Nordisk has some manufacturing capacity in Clayton, North Carolina. It's likely ...